Gil Beyen, Erytech Pharma CEO

French pen­ny stock will no longer knock on FDA door for ap­proval in a cer­tain type of blood can­cer

Things are not look­ing up for the French biotech Ery­tech Phar­ma.

The com­pa­ny is knock­ing off its plan to get FDA ap­proval for its drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.